This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
4 Aug 2014

Kallik Founder Recognised as One of Global Pharma Sector’s Most Valuable Contributors

Labelling content and artwork management leader Kallik is delighted to announce that its founder and CEO Neil Gleghorn has just been recognised as one of the 100 most influential people on the global pharmaceutical stage.

 

The honour is confirmed by Neil being named to the landmark PharmaVOICE 100 List published by the sector’s leading independent editorial publication, PharmaVOICE.

 

Established 9 years ago, The PharmaVOICE 100 is an annual list of individuals determined by their peers as having made the most consistent, outstanding contribution to the life sciences industry, an industry whose UK representatives generate over £50 billion in sales every year according to government statistics.

 

According to the publishers, winners of PharmaVOICE 100 places illustrate what it means to think bigger, do more, and lead with passion and integrity, with all nominations decided by members of the sector.
“I am extremely honoured to receive this industry recognition,” said Neil.

 

“It is one of the most important peer awards in the pharmaceutical industry, and is testament to the work of everyone here at Kallik — not just me, but everyone from the most junior team member all the way up to the board, our partners and everyone who’s been part of the journey – and most important of all, our customers.”

 

A Long-Lasting Dialogue

Neil’s extensive knowledge and understanding of the pharma industry’s specific challenges was key to his winning a PharmaVOICE 100 place.

 

That is a knowledge base that he has used to develop forward-thinking solutions that help achieve efficiency and compliance as well as form the basis for on-going dialogues with customers about the long-term challenges they face.

 

“What a third party like a Kallik can do is see the gaps that siloed teams in procurement, regulatory or marketing in a pharmaceutical company just can’t,” he said. “We use that perspective to develop the kind of systems that the pharmaceutical companies of today are increasingly recognising as vital in maximising their opportunity in the market.”
 

Related News